Jasper Therapeutics is a clinical-stage biotechnology company developing therapeutics targeting mast cell driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and asthma. Its lead product candidate, briquilimab, is a humanized monoclonal antibody blocking the SCF/KIT pathway to deplete mast cells. The company holds an exclusive license from Amgen for briquilimab and is advancing multiple Phase 1b/2a clinical trials including BEACON (CSU), SPOTLIGHT (CIndU), and ETESIAN (asthma).
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001213900-26-036426 | EDGAR | 99K words |
| 2025-02-28 | 2024-12-31 | 0001213900-25-018384 | EDGAR | 113K words |
| 2024-03-05 | 2023-12-31 | 0001213900-24-020114 | EDGAR | 91K words |
| 2023-03-08 | 2022-12-31 | 0001213900-23-018542 | EDGAR | — |
| 2022-03-18 | 2021-12-31 | 0001213900-22-013592 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001213900-21-018735 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001213900-20-007505 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001213900-26-089592 | EDGAR | 43K words |
| 2025-11-10 | 2025-09-30 | 0001213900-25-107884 | EDGAR | 39K words |
| 2025-08-13 | 2025-06-30 | 0001213900-25-075635 | EDGAR | 35K words |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042011 | EDGAR | 27K words |
| 2024-11-07 | 2024-09-30 | 0001213900-24-095173 | EDGAR | 32K words |
| 2024-08-13 | 2024-06-30 | 0001213900-24-067897 | EDGAR | 32K words |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042805 | EDGAR | 28K words |
| 2023-11-09 | 2023-09-30 | 0001213900-23-084970 | EDGAR | 34K words |
| 2023-08-11 | 2023-06-30 | 0001213900-23-066234 | EDGAR | 33K words |
| 2023-05-12 | 2023-03-31 | 0001213900-23-039021 | EDGAR | 29K words |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071165 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001213900-22-047382 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-26 | 0001213900-26-093979 | EDGAR | 1K words |
| 2026-08-14 | 0001213900-26-090055 | EDGAR | 2K words |
| 2026-08-03 | 0001213900-26-084687 | EDGAR | 1K words |
| 2026-07-31 | 0001213900-26-083563 | EDGAR | 1K words |
| 2026-07-17 | 0001213900-26-078887 | EDGAR | 4K words |
| 2026-07-16 | 0001213900-26-078781 | EDGAR | 3K words |
| 2026-03-30 | 0001213900-26-036448 | EDGAR | 3K words |
| 2026-01-08 | 0001213900-26-002329 | EDGAR | 3K words |
| 2026-01-07 | 0001213900-26-002185 | EDGAR | 1K words |
| 2025-12-02 | 0001213900-25-116943 | EDGAR | 3K words |
133 total filings indexed. 104 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001788028 |
| Ticker | JSPR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.jaspertherapeutics.com |
| Listed | 2021-09-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/JSPR (~200 tokens, structured JSON with cryptographic provenance)